Inventiva reports preliminary 2023 fiscal year financial : v

Revenues of €17.5 million for the full year of 2023, compared to €12.2 million for 2022Cash and cash equivalents at €26.9 million, short-term deposits at €...

Related Keywords

Tianqing , Zhejiang , China , Paris , France General , France , Boston , Massachusetts , United States , Russia , Ukraine , New York , Daix , Bourgogne , South Korea , Japan , Israel , French , Chinese , Julia Cailleteau , Pascaline Clerc , Aude Lepreux , Sino Biopharm , Nasdaq , Market Program , Health Care Conference , Products Administration , Corporate Affairs , European Investment Bank , Patricial Bank , Hepalys Pharma Inc , Chia Tai Tianqing Pharmaceutical Group Co Ltd , Brunswick Group , Data Monitoring Committee , Exchange Commission , Suspected Unexpected Serious Adverse Reaction , Long Island City , Euronext Paris , Chief Executive Officer , Hepalys Pharma , Data Monitoring , Investigational New Drug , Medical Products Administration , At The Market Program , Hepalys License , Informed Consent Form , Patient First Visit , Annual Health Care Conference , Paris Hepatology Conference , Annual Conference Liver Connect , Nasdaq Global Market , Roquet Montegon , Private Securities Litigation Reform Act , New Drug Application , Universal Registration Document , Des March , Annual Report , Half Year Report , Paris Stock Exchange Iva , Inventiva ,